摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-amino-ethoxymethyl)-5-oxo-4-pyridin-3-yl-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester | 848586-77-6

中文名称
——
中文别名
——
英文名称
2-(2-amino-ethoxymethyl)-5-oxo-4-pyridin-3-yl-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester
英文别名
ethyl 2-(2-aminoethoxymethyl)-5-oxo-4-pyridin-3-yl-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylate
2-(2-amino-ethoxymethyl)-5-oxo-4-pyridin-3-yl-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid ethyl ester化学式
CAS
848586-77-6
化学式
C20H25N3O4
mdl
——
分子量
371.436
InChiKey
ABRSELNWFRQZDM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    27
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    104
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • Dihydropyridine compounds for treating or preventing metabolic disorders
    申请人:Ono Mitsunori
    公开号:US20050203119A1
    公开(公告)日:2005-09-15
    This invention relates to dihydropyridine compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein A 2 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , and m are defined herein, and compositions comprising such compounds. The invention also relates to methods of preventing or treating metabolic disorders, such as diabetes mellitus, and conditions and complications associated with diabetes mellitus, comprising administering to a subject in need thereof a compound of formula (1) or a composition comprising such a compound. The invention further relates to kits comprising a compound of formula (I).
    本发明涉及式(I)的二氢吡啶化合物或其药学上可接受的盐、溶剂化合物、笼合物或前药,其中A2、R12、R13、R14、R15、R16、R17、R18、R19、R20、R21、R22和m如本文所定义,并且包括含有这种化合物的组合物。本发明还涉及预防或治疗代谢性疾病,如糖尿病以及与糖尿病相关的疾病和并发症的方法,包括向需要的受试者给予式(I)的化合物或包含这种化合物的组合物。本发明还涉及包含式(I)的化合物的试剂盒。
  • DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS
    申请人:Synta Pharmaceuticals Corporation
    公开号:EP1663227A2
    公开(公告)日:2006-06-07
  • [EN] DIHYDROPYRIDINE COMPOUNDS FOR TREATING OR PREVENTING METABOLIC DISORDERS<br/>[FR] COMPOSES DE DIHYDROPYRIDINE PERMETTANT DE TRAITER OU DE PREVENIR DES TROUBLES METABOLIQUES
    申请人:SYNTA PHAMACEUTICALS CORP
    公开号:WO2005025507A2
    公开(公告)日:2005-03-24
    This invention relates to dihydropyridine compounds of formula: (I) or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein A2, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, and m are defined herein, and compositions comprising such compounds. The invention also relates to methods of preventing or treating metabolic disorders, such as diabetes mellitus, and conditions and complications associated with diabetes mellitus, comprising administering to a subject in need thereof a compound of formula (I) or a composition comprising such a compound. The invention further relates to kits comprising a compound of formula (I).
  • [EN] 5,6,7,8-TETRAHYDROQUINOLINES AND RELATED COMPOUNDS AND USES THEREOF<br/>[FR] 5,6,7,8-TETRAHYDROQUINOLEINES ET COMPOSES ASSOCIES ET LEURS UTILISATIONS
    申请人:SYNTA PHARMACEUTICALS CORP
    公开号:WO2006065842A2
    公开(公告)日:2006-06-22
    [EN] This invention relates to substituted 5,6,7,8-tetrahydroquinoline compounds, substituted dihydropyridine compounds, and substituted tricyclic compounds. The invention also relates to methods of preventing or treating metabolic disorders, such as diabetes mellitus, and conditions and complications associated with diabetes mellitus, comprising administering to a subject in need thereof a compound of the invention or a composition comprising such a compound. The invention further relates to methods of treating inflammatory bowel disease, comprising administering to a subject in need thereof a compound of the invention or a composition comprising such a compound.
    [FR] Cette invention concerne des composés 5,6,7,8-tétrahydroquinoléines substitués, des composés dihydropyridines substitués et des composés tricycliques substitués. Cette invention concerne également des méthodes permettant de prévenir ou de traiter des troubles métaboliques, tels que le diabète sucré, ainsi que des états et des complications associés au diabète sucré, lesquelles méthodes consistent à administrer à un sujet nécessitant un tel traitement un composé de cette invention ou une composition contenant un tel composé. Cette invention concerne en outre des méthodes de traitement d'une maladie intestinale inflammatoire consistant à administrer à un sujet nécessitant un tel traitement un composé de cette invention ou une composition contenant un tel composé.
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-